Ana-Maria Tanase

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2020 · 150 citations · Full text

Asthma, Allergy, Twice-daily Fluticasone–salmeterol +7

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study

Richard N. van Zyl-Smit, Matthias Krüll, Yasuhiro Gon et al. · The Lancet Respiratory Medicine · 2020 · 48 citations

Asthma, Allergy, Clinical Allergy +9

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial

Fernando J. Martínez, Gerard J. Criner, Margret Jandl et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 41 citations · Full text

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma

Roland Buhl, Ana-Maria Tanase, Motoi Hosoe et al. · Pulmonary Pharmacology & Therapeutics · 2020 · 15 citations · Full text

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Kai Michael Beeh, Anne‐Marie Kirsten, Ana-Maria Tanase et al. · International Journal of COPD · 2018 · 13 citations · Full text